SAN DIEGO, May 11 /PRNewswire/ -- Alliance Pharmaceutical Corp. (Nasdaq: ALLP) announced today that two Phase 3 clinical (human) studies with Imagent(R) (AF0150) have successfully demonstrated a clinically and highly statistically significant improvement in visualization of the walls of the heart (endocardial border delineation) compared to standard (non-contrasted) ultrasound imaging. Enhanced visualization of the heart may allow better detection of cardiac abnormalities such as structural and functional defects. The results from these studies are being compiled for the filing of a New Drug Application with the U.S. Food and Drug Administration, and a Marketing Authorization Application in Europe. Imagent is being developed jointly by Alliance and Schering AG, Germany, and will be marketed exclusively by Schering AG.
The Imagent Phase 3 clinical studies were performed in approximately 500 patients at multiple medical centers throughout the U.S. Patients enrolled in the studies had undergone previous ultrasound (echocardiography) procedures that had not produced optimal images of the heart. Ultrasound images taken with and without Imagent were analyzed independently by cardiologists who did not otherwise participate in the studies. The results showed that use of Imagent provided clearer ultrasound images, potentially allowing for more accurate diagnoses. Detailed data from these studies are being prepared for publication.
Alliance is a pharmaceutical research and development company developing innovative medical products from novel scientific discoveries. Two additional products based on its proprietary perfluorochemical technologies are currently in Phase 3 clinical development: Oxygent(TM) (perflubron emulsion), an intravascular oxygen carrier ("blood substitute") to temporarily augment oxygen delivery in surgical and other patients at risk of acute tissue oxygen deficit; and LiquiVent(R) (neat perflubron), an intrapulmonary agent to reduce a patient's exposure to the harmful effects of conventional mechanical ventilation.
Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein, including the uncertainties associated with the conduct of preclinical or clinical studies and the timing or ability to investigate scientific data. Alliance refers you to cautionary information contained in documents the Company files with the Securities and Exchange Commission from time to time, including the last Form 10-K and Form 10-Q, and those risk factors set forth in the most recent registration statement on file.
For further information contact Gwen Rosenberg, Vice President, Corporate Communications, at (619) 558-4375.
SOURCE Alliance Pharmaceutical Corp.
/CONTACT: Gwen Rosenberg, Vice President, Corporate Communications of
Alliance Pharmaceutical Corp., 619-558-4375/ |
